Fred Schulte, Kaiser Health News
Five years in the past, Companion DX Reference Lab hoped to money in on cutting-edge genetic assessments paid for by Medicare.
The Houston lab marketed a check to evaluate how an individual’s genes have an effect on tolerance for medication similar to opiates used to deal with continual ache. It additionally ran DNA assessments to assist deal with most cancers and urine screens to watch drug abuse.
But the lab went bust final 12 months after Medicare ordered it to repay greater than $16 million for genetic assessments well being officers stated weren’t wanted.
Companion Dx is one in all a minimum of six medical labs mired in chapter courtroom after Medicare alleged they improperly billed the federal government for pointless urine, genetic or coronary heart illness assessments anticipated to trigger a whole bunch of hundreds of thousands in losses to taxpayers, an investigation by Kaiser Health News discovered.
As the nation’s invoice for drug and genetic assessments has climbed to an estimated $eight.5 billion a 12 months, there’s mounting suspicion amongst well being insurers that some testing might do extra to spice up revenue margins than assist deal with sufferers.
Medicare has slashed charges for urine assessments and tightened protection of some genetic screens, which might price Medicare $1,000 or extra per individual. Private insurers, who principally have paid these payments with out query, are also taking a extra penetrating have a look at spending on the controversial lab work.
Yet, getting these companies to repay Medicare and personal insurers stays a formidable problem. While some doctor-owned labs have dodged assortment efforts for years, a number of testing companies deeply in debt to Medicare seem to have few property to repay overcharges relationship again years, courtroom data present.
“Medicare shouldn’t be paying for dubious tests, but the time to catch that is in the very beginning when [labs] are asking for payment,” stated Steve Ellis, vice-president of Taxpayers for Common Sense, a price range watchdog group. “They need to increase oversight so the dollars don’t go out the door in the first place.”
A spokesman for the federal Centers for Medicare & Medicaid Services (CMS) had no remark. Neither did the Department of Justice, which represents the federal government’s pursuits in courtroom.
Labs can run a spread of genetic and drug assessments utilizing a saliva pattern, blood or urine specimen. The price ticket to Medicare can mount rapidly, particularly when medical doctors order extremely specialised assessments for giant numbers of sufferers. Two bankrupt labs that federal officers say routinely overused assessments to detect uncommon coronary heart illnesses within the aged, as an illustration, might find yourself owing the federal government a complete of greater than $200 million, courtroom data present.
Subscribe to KHN’s free Morning Briefing.
Sign Up Please affirm your electronic mail tackle under: Sign Up
Some labs have saved working in chapter whereas others liquidated tools and offered off property. Several chapter trustees, whose obligation is to ferret out property, are suing suppliers, insurers and a few medical doctors to recuperate funds.
Whether they will increase the pile of money wanted to repay Medicare is uncertain.
Companion Dx, in line with chapter data, had $117,497 money available on the finish of September. Medicare is looking for the return of $16.2 million paid to the corporate for companies “not considered medically necessary,” in line with a January court filing.
The Texas lab had no remark, however in courtroom filings has blamed its collapse on disagreements with Medicare over the deserves of its assessments and authorities audits that retroactively disallowed claims. Medicare pays just for companies it deems “medically necessary,” and audits usually take a few years to finish.
Companion Dx opened in January 2012 anticipating to “capture favorable profit margins that existed in connection with this cutting edge technology,” the corporate wrote in its chapter submitting.
However, beginning in 2013, Medicare started having second ideas concerning the validity of some assessments and in the end determined to cowl them on simply 1 % of sufferers, in line with the corporate. The lab declared chapter in July 2016. The case is pending.
Iverson Genetic Diagnostics Inc. is one other lab that turned to chapter courtroom as Medicare tried to reclaim $19.7 million, court records show. The case is pending.
Medicare took purpose on the Seattle agency in November 2013 after reviewing “numerous” complaints of billings for genetic assessments that sufferers “had not actually received,” federal officers wrote in a courtroom submitting.
A later federal audit concluded that Iverson had charged Medicare for assessments that have been “not reasonable and necessary.” In September 2015, about two months after Medicare known as for the refund, the lab filed for chapter.
Iverson denied overbilling Medicare and is interesting the Medicare choice, which it stated in a courtroom submitting “was not based upon sufficient or proper evidence.” And Iverson denied wrongdoing in courtroom filings.
Neither the lab, now situated in Charleston, S.C., nor its legal professionals would remark.
In one other case, Pharmacogenetics Diagnostic Laboratory LLC in Louisville exited chapter in late October with out repaying Medicare $26.three million for disallowed genetic assessments. The lab, arrange in 2004 by two University of Louisville professors, strongly disputed Medicare’s findings however stated they have been the “primary reason” for the chapter, courtroom data present.
Charity Neukomm, a lawyer for the lab, stated one other medical group agreed to buy all its property “free and clear of liens.” That left nothing for the federal government.
There’s additionally little probability that Natural Molecular Testing Corp., a defunct genetic testing lab, will repay the $71 million it owes Medicare, in line with John Kaplan, an legal professional for the chapter trustee.
Kaplan stated the lab close to Seattle, which opened in 2010, was “printing money from billing Medicare” till the federal government suspended funds in April 2013. The firm filed for chapter in 2013 within the face of a Medicare audit of its billing and concern over its enterprise practices, similar to paying some medical doctors who ordered its assessments as a lot as $10,000 a month in consulting charges, in line with courtroom data.
Five years in, the chapter case is anticipated to settle subsequent 12 months, however there’s more likely to be “no cash left” to repay Medicare, Kaplan stated.
Critics argue that Medicare has been gradual to evaluate the advantages of latest and controversial assessments and applied sciences — even when hovering prices signaled a warning of attainable overuse.
Spending on genetic testing, for instance, shot up from about $167 million in 2013 to greater than $466 million a 12 months later, in line with Medicare billing information. In 2015, this system spent about $317 million on the assessments and a few $165 million final 12 months. Government auditors credit score tighter oversight for the sharp decline in billing.
Ellis, the price range watchdog, stated the “huge jump” in these payments ought to have “sent out a red flag.”
Medicare officers don’t routinely confirm that the gross sales claims labs make to medical doctors are rooted in scientific proof. Some labs have hawked genetic assessments as a instrument for making ache administration safer. The labs contend the assessments can pinpoint the correct medication and dosage for every affected person primarily based on their genetic make-up, thus lowering the specter of overdose or different harm.
However, many consultants argue that the science hasn’t caught as much as the gross sales pitch — and that some high-priced assessments might do little to diagnose or deal with sickness.
Genetic assessments “are not ready for prime time,” stated Charles Argoff, professor of neurology at Albany Medical College in New York. He stated their affect on medical care “hasn’t been measured.”
Court data present that the authorized battles to recuperate property from failed labs typically plod on for years, particularly when trustees consider labs paid unlawful charges or different kickbacks to steer medical doctors to order doubtful assessments.
“Some of these cases never go away,” stated David Schumacher, a Boston well being care lawyer who has defended medical doctors towards these claims. Still, he stated that even after years of authorized wrangling Medicare typically is unlikely to “be made whole and fully repaid.”
The trustee for Heart Diagnostic Laboratory, which marketed a panel of blood assessments to detect coronary heart illness and different diseases earlier than its June 2015 chapter, has filed greater than three dozen lawsuits to recuperate cash paid to medical doctors and medical places of work, together with suspect consulting charges.
“Our analysis is that all of these payments were tainted and therefore we’re entitled to go after them,” stated Richard Kanowitz. He added: “It’s an uphill battle.”
Kaiser Health News (KHN) is a nationwide well being coverage information service. It is an editorially impartial program of the Henry J. Kaiser Family Foundation which isn’t affiliated with Kaiser Permanente.